Clinical characteristics of CKD patients stratified by OH values.

<p>Clinical characteristics of CKD patients stratified by OH values.</p

Determinants of eGFR decline in entire cohort (n = 312).

<p>Determinants of eGFR decline in entire cohort (n = 312).</p

Hazard ratio of diuretic users and non-users in relation to renal outcomes.

<p>Hazard ratio of diuretic users and non-users in relation to renal outcomes.</p

Comparison of outcomes between diuretic users and non-users.

<p>Comparison of outcomes between diuretic users and non-users.</p

Baseline value of eGFR in different fluid status categories with respect to diuretic use.

<p>Baseline value of eGFR in different fluid status categories with respect to diuretic use.</p

Distribution of absolute overhydration (0H) in 312 NDD-CKD patients, ranging between -2.1–4.4 L (82± 1.79).

<p>Distribution of absolute overhydration (0H) in 312 NDD-CKD patients, ranging between -2.1–4.4 L (82± 1.79).</p

ROC Curve analysis of Multivariate regression model of AKI among dengue patients.

<p>ROC Curve analysis of Multivariate regression model of AKI among dengue patients.</p

Study Methodology Flow Diagram.

<p>Study Methodology Flow Diagram.</p

Short-term renal outcomes following acute kidney injury among dengue patients: A follow-up analysis from large prospective cohort - Fig 2

<p>Mean values of SCr (A) and eGFR (B) among dengue patients with and without AKI at hospital admission and discharge.</p

Comparison of patients with DVI with and without AKI.

<p>Multiple organ dysfunctions is referred as dysfunction of ≥2 organ systems; DF: dengue fever, DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome; CKD: chronic kidney disease, IHD: ischemic heart disease, DM: diabetes mellitus, CHF: congestive heart failure; HPL: hyperlipidemia, PT: prothrombin time, aPTT: activated partial thromboplastin time</p><p>*Fisher exact test, student <i>t</i> test or Mann-Whitney <i>U</i> test, where appropriate</p><p>**Significant</p><p>¹Phi coefficient (0.1–0.29)</p><p>²Phi coefficient (0.3–0.49)</p><p>³Phi coefficient (0.5–1.0)</p><p>⁴Cramer`s V coefficient (0.3–0.49)</p><p>Comparison of patients with DVI with and without AKI.</p